attia glp 1 320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape Frontiers | GLP-1R in diabetes

Not every patient wants surgery

These findings suggest that even in a weight-reduced state from untreated obesity, the DVC amylin and GLP-1 receptors continue to be a viable drug target for sustained weight loss

Quercetins clinical impact needs confirmation in larger trials, but it exemplifies how a well-known dietary phytochemical is being repurposed at higher doses for cardiovascular prevention

Work in a clean area with gloves, swab both vial stoppers with alcohol, draw the calculated volume of bacteriostatic water with a sterile syringe, and inject it slowly down the inner wall of the peptide vial

The percentage of patients who achieved a clinically meaningful treatment response (defined as achieving at least 5% weight loss after 1 year of treatment) ranged from 36% to 57% with CONTRAVE, compared to 17% to 43% with placebo